Please provide your email address to receive an email when new articles are posted on . Monthly seizure frequency percentage reduction was 68.73% for the entire study cohort. For those followed up in ...

In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...

Adults with focal onset seizures experienced significant reductions in their seizure frequency with azetukalner, according to ...

Xenon Pharmaceuticals’ bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient ...

The study sought to evaluate the efficacy, safety, and tolerability of azetukalner, administered as an oral, adjunctive, once ...

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over ...

With the 25 mg dose, reductions in weekly seizures were seen in the first week of treatment, she noted. At 12 weeks, Patient ...

Share on Pinterest A new drug reduced seizures in subjects with treatment resistant epilepsy in a recent clinical trial. The Good Brigade/Getty Images Researchers say a new medication may potentially ...

Adding the novel drug XEN1101 to current antiseizure regimens significantly decreases seizures in patients with treatment-resistant focal epilepsy and can safely be taken at its highest dose, results ...

A study found that most individuals diagnosed with focal epilepsy take over a year and more than one medication to be free of seizures. The study, led by researchers from the U.S. and Australia and ...

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Neurelis, Inc., today announced details of two poster presentations at the American Academy of Neurology (AAN) Annual Meeting ...